Fennec Pharmaceuticals Inc. (FENC) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen, and welcome to FENIC Pharmaceuticals Second Quarter 2026 Earnings and Corporate Update Conference Call. At this time, all participants are in listen-only mode. Later, we'll conduct a question and answer session, and instructions on how to participate will be given at that time. As a reminder, today's conference call is being recorded. Now, I'd like to turn the conference over to FENIC's Chief Financial Officer, Robert Andrade. Thank you, Operator, and good morning, everyone. We would like to thank you for joining us. We are pleased to host Fennec Pharmaceuticals' second quarter 2026 earnings conference call today, during which we will review our financial results, as well as provide a general business update. Joining me from Fennec this morning is our chief executive officer and board member, Jeff Hackman, our chief commercial officer, Terry Evans, and our chief medical officer, Dr. Pierre Sayad. I am also pleased to welcome our Chief Strategy Officer, Christy Cioffi, who is joining our earnings call for the first time. Christy has more than two decades of leadership experience spanning commercial strategy, brand building, and organizational development, including nearly 15 years of expertise leading award-winning commercialization and launch strategies across the product lifecycle. She has held senior commercial leadership roles at a number of leading biopharmaceutical companies, including Shield Therapeutics, Stemline Therapeutics, Yusa Pharma, CarioPharm Therapeutics, Servier, previously Shire, Exalta, Baxter, and Abbott Laboratories, where she helped build and grow oncology, rare disease, and hematology brands from early development through commercialization. As a graduate of West Point, Christy also served our country as a dec...